Treats moderate acne vulgaris in females at least 15 years of age. ANDA 200383, held by Naari Pte. Ethinyl Estradiol; Norgestimate.
As of Nov 16, 2026, ANDA 200383 (Norgestimate And Ethinyl Estradiol), held by Naari Pte, was first approved by FDA on Apr 7, 2015, with 4 approved supplements and 0 published complete response letters.
Norgestimate and Ethinyl Estradiol Tablets USP are combinations of norgestimate, a progestin, and ethinyl estradiol, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. Norgestimate and Ethinyl Estradiol Tablets USP is indicated for the treatment of moderate acne vulgaris in females at least 15 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Norgestimate and Ethinyl Estradiol Tablets USP should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. 1.1 Oral Contraceptive
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 7, 2015 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Norgestimate And Ethinyl Estradiol0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG · tablet;oral-28 | Ethinyl Estradiol; Norgestimate | Rx |
| Oct 3, 2023 | Supplement 5Labeling · Standard review | Approved | None posted |
| Apr 29, 2022 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 2, 2022 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 2, 2022 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 7, 2015 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters